Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 367 active entries
400 Boulevard Gonthier d’Andernach - Parc d’Innovation
67405 Illkirch Graffenstaden Cedex
France Phone: +33 (0)3 88 27 91 00
Fax: +33 (0)3 88 22 58 07
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Stock symbol: TNG
Description:
Transgene is a biotech company developing myvac®, Individualized Neoantigen Therapeutic Vaccines (INTV) platform designed to prevent cancer recurrence and a portfolio of virus-based candidates. Our therapies, from our myvac® platform, are tailor‑made for each patient based on the unique genetic characteristics of their tumors. They harness the mechanisms of patients' immune responses to enable them to fight against an existing disease. Our most advanced drug candidate, TG4050, is in a Phase 2 clinical trial in patients with resected head and neck cancer. TG4070, the second candidate from the myvac® platform, reflects the important strategic expansion of the myvac® platform to non-small cell lung cancer. Integrating Transgene’s proprietary AI-driven neoantigen selection and cell line manufacturing capabilities, TG4070 is positioned as a novel vaccine that could be applied to multiple tumor types. The Company, based in Strasbourg, employs approximately 160 people, 70% of whom are dedicated to research and development. It is listed on the regulated market of Euronext in Paris (TNG, Compartment B).
Selected Categories:
Last update of this entry: September 22, 2026
|